Progress in Multiple Sclerosis Research
Nova Publishers, 2005 - Broj stranica: 209
Multiple sclerosis (MS) is a life-long chronic disease diagnosed primarily in young adults. During an MS attack, inflammation occurs in areas of the white matter of the central nervous system (nerve fibres that are the site of MS lesions) in random patches called plaques. This process is followed by destruction of myelin, which insulates nerve cell fibres in the brain and spinal cord. Myelin facilitates the smooth, high-speed transmission of electrochemical messages between the brain, the spinal cord, and the rest of the body. The initial symptom of MS is often blurred or double vision, red-green colour distortion, or even blindness in one eye. Most MS patients experience muscle weakness in their extremities and difficulty with co-ordination and balance. Most people with MS also exhibit paresthesias, transitory abnormal sensory feeling such as numbness or "pins and needles." Some may experience pain or loss of feeling. About half of people with MS experience cognitive impairments such as difficulties with concentration, attention, memory, and judgement. This volume presents leading research from around the globe.
Što ljudi govore - Napišite recenziju
Na uobičajenim mjestima nismo pronašli nikakve recenzije.
action acuities addition appear assessment associated axonal Azathioprine brain cause cells changes chronic illness clinical cognitive combination common compared controls correlates countries Croatia cytokines death decreased demonstrated demyelination depression described differences disability disease disorders effects Epidemiology et al evidence experience expression factors findings frequent functional further genetic Glatiramer acetate Gorski Kotar higher human IFN-B imaging immune important incidence incontinence increased indicate individuals infection influence Interferon Italy lesions levels living magnetic resonance mean measures mechanisms mortality rates multiple sclerosis Neurol Neurology observed participants patients patterns performance period persons physical activity population possible present prevalence problems production progressive psychiatric recently reduced regions relapse relapsing-remitting relationship reported response risk role scores secondary sexuality significant social specific suggest symptoms Table therapy treatment understanding University virus visual women
Stranica 72 - The IFNB Multiple Sclerosis Study Group. Interferon beta-lb is effective in relapsingremitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology 1993; 43: 655-61.
Stranica 71 - European Study Group on Interferon beta-lb in Secondary Progressive MS. Placebocontrolled multicentre randomized trial of Interferon beta-lb in treatment of secondary progressive multiple sclerosis.
Stranica 92 - Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?
Stranica 91 - European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging— measured disease activity and burden in patients with relapsing multiple sclerosis.
Stranica 91 - Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999;103:807815.
Stranica 134 - AM, et al. Intramuscular interferon beta- la for disease progression in relapsing multiple sclerosis.
Stranica 135 - PRISMS (prevention of relapses and disability by interferon beta- la subcutaneously in multiple sclerosis) study group (1998) Randomised double-blind placebo-controlled study of interferon beta- la in relapsing/remitting multiple sclerosis.
Stranica 153 - Poser CM, Paty DW, Scheinberg L et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231 96.
Stranica 154 - GJ et al (1999) Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology 52:1626-1632 15.